ResMed Company Profile (NYSE:RMD)

About ResMed (NYSE:RMD)

ResMed logoResMed Inc. is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases. SDB includes obstructive sleep apnea (OSA) and other respiratory disorders that occur during sleep. Its cloud-based software digital health applications, along with its devices, are designed to provide connected care to improve patient outcomes. The Company's portfolio of products includes devices, diagnostic products, mask systems, headgear and other accessories, dental devices, portable oxygen concentrators (POCs) and cloud-based software informatics solutions. The Company produces Continuous Positive Airway Pressure (CPAP), Variable Positive Airway Pressure (VPAP) and AutoSet systems for the titration and treatment of SDB.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Advanced Medical Equipment & Technology - NEC
  • Sub-Industry: Health Care Equipment
  • Symbol: NYSE:RMD
  • CUSIP: 76115210
  • Web: www.resmed.com
Capitalization:
  • Market Cap: $10.92008 billion
  • Outstanding Shares: 141,819,000
Average Prices:
  • 50 Day Moving Avg: $76.55
  • 200 Day Moving Avg: $71.27
  • 52 Week Range: $56.59 - $79.44
P/E:
  • Trailing P/E Ratio: 33.86
  • Foreward P/E Ratio: 24.74
  • P/E Growth: 2.61
Sales & Book Value:
  • Annual Revenue: $2.03 billion
  • Price / Sales: 5.39
  • Book Value: $13.08 per share
  • Price / Book: 5.90
Dividend:
  • Annual Dividend: $1.32
  • Dividend Yield: 1.7%
Profitability:
  • EBIDTA: $559.02 million
  • Net Margins: 15.96%
  • Return on Equity: 22.53%
  • Return on Assets: 11.89%
Debt:
  • Debt-to-Equity Ratio: 0.63%
  • Current Ratio: 4.77%
  • Quick Ratio: 4.00%
Misc:
  • Average Volume: 736,544 shs.
  • Beta: 0.84
  • Short Ratio: 13.02
 
Frequently Asked Questions for ResMed (NYSE:RMD)

What is ResMed's stock symbol?

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

How often does ResMed pay dividends? What is the dividend yield for ResMed?

ResMed declared a quarterly dividend on Thursday, April 27th. Shareholders of record on Thursday, May 11th will be paid a dividend of $0.33 per share on Thursday, June 15th. This represents a $1.32 dividend on an annualized basis and a dividend yield of 1.71%. The ex-dividend date is Tuesday, May 9th. View ResMed's Dividend History.

How were ResMed's earnings last quarter?

ResMed Inc. (NYSE:RMD) released its quarterly earnings data on Thursday, April, 27th. The company reported $0.71 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.70 by $0.01. The company had revenue of $514.20 million for the quarter, compared to the consensus estimate of $525.84 million. ResMed had a return on equity of 22.53% and a net margin of 15.96%. The business's revenue for the quarter was up 13.3% compared to the same quarter last year. During the same quarter last year, the company earned $0.68 EPS. View ResMed's Earnings History.

Where is ResMed's stock going? Where will ResMed's stock price be in 2017?

10 brokerages have issued 1-year price objectives for ResMed's stock. Their predictions range from $50.00 to $72.00. On average, they anticipate ResMed's share price to reach $61.29 in the next year. View Analyst Ratings for ResMed.

What are analysts saying about ResMed stock?

Here are some recent quotes from research analysts about ResMed stock:

  • 1. According to Zacks Investment Research, "In the last one month, ResMed is trading significantly above the broader Medical Products industry. On the brighter side, ResMed’s product launches and strategies to gain traction in the SDB market are expected to boost its performance in the near term. Moreover, the company’s double-digit growth in mask sales raises optimism. Its recent published favorable study result on COPD is expected to open up new scope in this line. Yet, challenges like competitive bidding and reimbursement issues continue to plague the stock. Foreign exchange movements dented third-quarter earnings, thanks to the weaker Euro and stronger Australian dollar relative to the U.S. dollar. Rising operating expenses and a weak operating margin are other major woes for ResMed. The company’s last reported fiscal third quarter performance was also unimpressive." (7/6/2017)
  • 2. Needham & Company LLC analysts commented, "RMD’s revenue and EPS beat consensus in F2Q17. RMD’s gross margin was lower than expected as price declines and mix (both product and geographic) were partially offset by manufacturing efficiencies and the Brightree acquisition. However, this was offset by lower than expected SG&A and R&D expense and RMD’s operating margin beat our estimate. Despite the headline results, this wasn’t a clean quarter in our view since flow generator growth of 17% CC was helped by a few temporary factors (the AirStart liquidation and some stocking orders in China), mask growth was disappointing at 2% CC, and gross margin declined significantly on an organic basis." (1/24/2017)

Who are some of ResMed's key competitors?

Who are ResMed's key executives?

ResMed's management team includes the folowing people:

  • Rob Douglas, President, Chief Operating Officer
  • Michael Farrell, Chief Executive Officer, Director
  • Brett A. Sandercock, Chief Financial Officer
  • Jim Hollingshead Ph.D., President - Americas
  • Anne Reiser, President – Europe & Asia Pacific
  • David Pendarvis, Chief Administrative Officer, Global General Counsel, Company Secretary
  • Agnes Lee, Senior Director - Investor Relations
  • Peter C. Farrell Ph.D., Non-Executive Chairman of the Board
  • Ron Taylor, Lead Independent Director
  • Carol J. Burt, Independent Director

Who owns ResMed stock?

ResMed's stock is owned by many different of institutional and retail investors. Top institutional shareholders include APG Asset Management N.V. (0.22%), Russell Investments Group Ltd. (0.20%), Capital Investment Services of America Inc. (0.15%), Professional Advisory Services Inc. (0.13%), Rockefeller Financial Services Inc. (0.13%) and National Pension Service (0.11%). Company insiders that own ResMed stock include Anne Reiser, Brett Sandercock, Christopher G Roberts, David Pendarvis, Donald Darkin, Franz Kozich, Gary W Pace, James Hollingshead, John P Wareham, Jr Gregor K Emmert, Michael J Farrell, Peter C Farrell, Richard Sulpizio, Robert Andrew Douglas, Ronald R Taylor and Warren Russell Hawkins. View Institutional Ownership Trends for ResMed.

Who sold ResMed stock? Who is selling ResMed stock?

ResMed's stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Bank of Montreal Can, APG Asset Management N.V., Professional Advisory Services Inc., Assenagon Asset Management S.A., Financial Architects Inc, Capital Investment Services of America Inc. and US Bancorp DE. Company insiders that have sold ResMed stock in the last year include Brett Sandercock, Christopher G Roberts, David Pendarvis, Gary W Pace, James Hollingshead, John P Wareham, Michael J Farrell, Peter C Farrell, Richard Sulpizio and Ronald R Taylor. View Insider Buying and Selling for ResMed.

Who bought ResMed stock? Who is buying ResMed stock?

ResMed's stock was purchased by a variety of institutional investors in the last quarter, including Copeland Capital Management LLC, BB&T Corp, Mn Services Vermogensbeheer B.V., Gateway Investment Advisers LLC, National Pension Service, Aperio Group LLC, BTIM Corp. and West Coast Financial LLC. Company insiders that have bought ResMed stock in the last two years include Franz Kozich, Jr Gregor K Emmert, Ronald R Taylor and Warren Russell Hawkins. View Insider Buying and Selling for ResMed.

How do I buy ResMed stock?

Shares of ResMed can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ResMed's stock price today?

One share of ResMed stock can currently be purchased for approximately $77.19.


MarketBeat Community Rating for ResMed (NYSE RMD)
Community Ranking:  1.5 out of 5 ( )
Outperform Votes:  157 (Vote Outperform)
Underperform Votes:  361 (Vote Underperform)
Total Votes:  518
MarketBeat's community ratings are surveys of what our community members think about ResMed and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ResMed (NYSE:RMD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Sell Ratings, 4 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 1.80)
Consensus Price Target: $61.29 (20.60% downside)

Analysts' Ratings History for ResMed (NYSE:RMD)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/12/2017BMO Capital MarketsReiterated RatingHoldLowView Rating Details
4/28/2017Citigroup Inc.DowngradeBuy -> NeutralHighView Rating Details
4/28/2017Jefferies Group LLCReiterated RatingSell$56.00LowView Rating Details
4/20/2017J P Morgan Chase & CoDowngradeOverweight -> Neutral$72.00 -> $71.00MediumView Rating Details
4/13/2017William BlairReiterated RatingOutperformLowView Rating Details
2/6/2017Canaccord GenuityReiterated RatingHold$59.00N/AView Rating Details
1/24/2017Needham & Company LLCReiterated RatingSellN/AView Rating Details
1/24/2017Barclays PLCBoost Price TargetUnderweight$55.00 -> $60.00N/AView Rating Details
9/29/2016Bank of America CorporationUpgradeNeutral -> Buy$89.00 -> $72.00N/AView Rating Details
8/29/2016Northland SecuritiesSet Price TargetSell$50.00N/AView Rating Details
4/27/2016MacquarieUpgradeUnderperform -> NeutralN/AView Rating Details
4/27/2016Piper Jaffray CompaniesDowngradeOverweight -> Neutral$65.00 -> $57.00N/AView Rating Details
1/22/2016Credit Suisse GroupUpgradeNeutral -> OutperformN/AView Rating Details
10/6/2015Deutsche Bank AGUpgradeSell -> Hold$53.00 -> $56.00N/AView Rating Details
9/24/2015Goldman Sachs Group, Inc. (The)UpgradeNeutral -> Conviction-BuyN/AView Rating Details
7/31/2015Morgan StanleyUpgradeEqual Weight -> OverweightN/AView Rating Details
(Data available from 7/25/2015 forward)

Earnings

Earnings History for ResMed (NYSE:RMD)
Earnings by Quarter for ResMed (NYSE:RMD)
Earnings History by Quarter for ResMed (NYSE RMD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/27/2017Q3 2017$0.70$0.71$525.84 million$514.20 millionViewN/AView Earnings Details
1/23/2017Q217$0.70$0.73$518.60 million$530.40 millionViewN/AView Earnings Details
10/25/2016Q117$0.64$0.62$475.05 million$465.45 millionViewListenView Earnings Details
7/28/2016Q416$0.74$0.74$512.37 million$518.60 millionViewListenView Earnings Details
4/26/2016Q316$0.69$0.68$455.32 million$453.90 millionViewListenView Earnings Details
1/21/2016Q216$0.66$0.69$445.46 million$454.54 millionViewListenView Earnings Details
10/22/2015Q116$0.59$0.58$406.26 million$411.70 millionViewListenView Earnings Details
7/30/2015Q415$0.65$0.68$436.27 million$453.10 millionViewListenView Earnings Details
4/23/2015Q315$0.65$0.65$425.76 million$422.50 millionViewListenView Earnings Details
1/22/2015Q215$0.62$0.64$408.20 million$423.00 millionViewListenView Earnings Details
10/23/2014Q115$0.58$0.58$375.00 million$380.40 millionViewListenView Earnings Details
7/31/2014Q414$0.66$0.64$433.42 million$415.20 millionViewListenView Earnings Details
4/23/2014Q314$0.64$0.63$401.00 million$397.80 millionViewListenView Earnings Details
1/23/2014Q214$0.63$0.60$398.09 million$384.30 millionViewListenView Earnings Details
10/24/2013Q114$0.58$0.56$372.28 million$357.66 millionViewListenView Earnings Details
8/1/2013Q4 2013$0.62$0.62$410.89 million$414.60 millionViewListenView Earnings Details
4/25/2013Q3 2013$0.58$0.58$386.76 million$383.60 millionViewListenView Earnings Details
1/24/2013Q2 2013$0.51$0.53$363.76 million$376.50 millionViewListenView Earnings Details
10/25/2012$0.46$0.49ViewN/AView Earnings Details
8/2/2012$0.49$0.53ViewN/AView Earnings Details
4/26/2012$0.41$0.44ViewN/AView Earnings Details
1/26/2012$0.38$0.42ViewN/AView Earnings Details
10/24/2011$0.35$0.33ViewN/AView Earnings Details
8/4/2011$0.37$0.37ViewN/AView Earnings Details
4/28/2011$0.35$0.35ViewN/AView Earnings Details
1/27/2011$0.36$0.37ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ResMed (NYSE:RMD)
2017 EPS Consensus Estimate: $2.71
2018 EPS Consensus Estimate: $2.99
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.57$0.64$0.61
Q2 20173$0.69$0.70$0.69
Q3 20173$0.65$0.70$0.68
Q4 20173$0.70$0.76$0.73
Q1 20182$0.65$0.65$0.65
Q2 20182$0.77$0.78$0.78
Q3 20182$0.75$0.76$0.76
Q4 20182$0.78$0.83$0.81
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for ResMed (NYSE:RMD)
Most Recent Dividend:6/15/2017
Annual Dividend:$1.32
Dividend Yield:1.71%
Dividend Growth:14.50% (3 Year Average)
Payout Ratio:57.64% (Trailing 12 Months of Earnings)
47.14% (Based on This Year's Estimates)
42.31% (Based on Next Year's Estimates)
Dividend Payments by Quarter for ResMed (NYSE:RMD)

Dividend History by Quarter for ResMed (NYSE RMD)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/27/2017quarterly$0.331.94%5/9/20175/11/20176/15/2017
1/23/2017quarterly$0.331.89%2/7/20172/9/20173/16/2017
10/25/2016quarterly$0.332.18%11/8/201611/10/201612/15/2016
7/28/2016quarterly$0.331.92%8/16/20168/18/20169/22/2016
4/26/2016quarterly$0.302.12%5/17/20165/19/20166/16/2016
1/21/2016quarterly$0.302.08%2/9/20162/11/20163/17/2016
10/22/2015quarterly$0.302.13%11/17/201511/19/201512/17/2015
7/30/2015quarterly$0.302.07%8/18/20158/20/20159/17/2015
4/24/2015quarterly$0.281.7%5/19/20155/21/20156/18/2015
1/23/2015quarterly$0.281.72%2/10/20152/12/20153/19/2015
10/27/2014quarterly$0.282.17%11/18/201411/20/201412/18/2014
8/1/2014quarterly$0.282.25%8/19/20148/21/20149/18/2014
4/24/2014quarterly$0.252.11%5/16/20145/20/20146/17/2014
1/24/2014quarterly$0.252.28%2/14/20142/19/20143/19/2014
10/25/2013quarterly$0.252.02%11/15/201311/19/201312/18/2013
8/2/2013quarterly$0.252.09%8/16/20138/20/20139/17/2013
4/29/2013quarterly$0.171.44%5/17/20135/21/20136/18/2013
1/25/2013quarterly$0.171.41%2/14/20132/19/20133/19/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for ResMed (NYSE:RMD)
Insider Ownership Percentage: 1.97%
Institutional Ownership Percentage: 60.73%
Insider Trades by Quarter for ResMed (NYSE:RMD)
Institutional Ownership by Quarter for ResMed (NYSE:RMD)
Insider Trades by Quarter for ResMed (NYSE:RMD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/14/2017James HollingsheadInsiderSell7,140$77.43$552,850.20View SEC Filing  
7/5/2017Peter C FarrellDirectorSell20,000$76.50$1,530,000.00View SEC Filing  
7/3/2017Brett SandercockCFOSell1,250$77.44$96,800.00View SEC Filing  
7/3/2017David PendarvisInsiderSell6,364$77.36$492,319.04View SEC Filing  
6/29/2017Jr. Gregor K EmmertInsiderBuy282,000$0.07$19,740.00
6/28/2017Jr. Gregor K EmmertInsiderBuy424,000$0.06$25,440.00
6/22/2017Richard SulpizioDirectorSell65,887$77.82$5,127,326.34View SEC Filing  
6/15/2017Gary W PaceDirectorSell24,390$76.00$1,853,640.00View SEC Filing  
6/5/2017David PendarvisInsiderSell6,365$72.62$462,226.30View SEC Filing  
6/5/2017Peter C FarrellDirectorSell20,000$72.65$1,453,000.00View SEC Filing  
6/1/2017Brett SandercockCFOSell1,250$71.02$88,775.00View SEC Filing  
5/4/2017Peter C FarrellDirectorSell20,000$68.75$1,375,000.00View SEC Filing  
5/3/2017David PendarvisInsiderSell6,365$69.55$442,685.75View SEC Filing  
5/1/2017Brett SandercockCFOSell1,250$68.60$85,750.00View SEC Filing  
4/17/2017James HollingsheadInsiderSell7,139$68.37$488,093.43View SEC Filing  
4/4/2017Peter C FarrellDirectorSell20,000$70.67$1,413,400.00View SEC Filing  
4/3/2017Brett SandercockCFOSell1,250$71.65$89,562.50View SEC Filing  
4/3/2017David PendarvisInsiderSell6,365$71.59$455,670.35View SEC Filing  
3/1/2017Brett SandercockCFOSell1,250$72.48$90,600.00View SEC Filing  
2/24/2017John P WarehamDirectorSell28,403$71.77$2,038,483.31View SEC Filing  
2/20/2017Christopher G RobertsDirectorSell10,000$71.91$719,100.00View SEC Filing  
2/15/2017Franz KozichDirectorBuy50,000$0.05$2,500.00
2/14/2017Warren Russell HawkinsDirectorBuy60,000$0.05$3,000.00
2/6/2017Peter C FarrellDirectorSell20,000$68.32$1,366,400.00View SEC Filing  
2/3/2017David PendarvisInsiderSell6,365$67.16$427,473.40View SEC Filing  
1/17/2017James HollingsheadInsiderSell7,084$64.44$456,492.96View SEC Filing  
1/4/2017Peter C FarrellDirectorSell20,000$62.14$1,242,800.00View SEC Filing  
1/3/2017David PendarvisInsiderSell6,365$61.95$394,311.75View SEC Filing  
12/5/2016David PendarvisInsiderSell6,365$60.00$381,900.00View SEC Filing  
12/5/2016Peter C FarrellDirectorSell20,000$59.83$1,196,600.00View SEC Filing  
11/4/2016Peter C FarrellDirectorSell20,000$57.28$1,145,600.00View SEC Filing  
11/3/2016David PendarvisInsiderSell6,033$57.79$348,647.07View SEC Filing  
10/18/2016James HollingsheadInsiderSell1,967$64.71$127,284.57View SEC Filing  
10/17/2016James HollingsheadInsiderSell5,264$64.43$339,159.52View SEC Filing  
10/17/2016Michael J FarrellCEOSell5,975$64.25$383,893.75View SEC Filing  
10/4/2016Peter C FarrellDirectorSell20,000$64.70$1,294,000.00View SEC Filing  
10/3/2016David PendarvisInsiderSell6,000$63.95$383,700.00View SEC Filing  
9/15/2016Michael J. FarrellCEOSell5,975$64.84$387,419.00View SEC Filing  
9/6/2016David PendarvisInsiderSell6,000$67.18$403,080.00View SEC Filing  
9/6/2016Peter C FarrellDirectorSell20,000$67.29$1,345,800.00View SEC Filing  
8/19/2016Gary W PaceDirectorSell36,000$69.93$2,517,480.00View SEC Filing  
8/17/2016Ronald R TaylorDirectorBuy2,487$69.13$171,926.31View SEC Filing  
8/16/2016Ronald R TaylorDirectorSell23,102$69.25$1,599,813.50View SEC Filing  
8/15/2016Michael J. FarrellCEOSell5,975$70.41$420,699.75View SEC Filing  
8/11/2016Brett SandercockCFOSell35,000$70.50$2,467,500.00View SEC Filing  
8/10/2016Richard SulpizioDirectorSell36,000$70.15$2,525,400.00View SEC Filing  
8/8/2016John P WarehamDirectorSell24,390$70.32$1,715,104.80View SEC Filing  
8/4/2016Peter C FarrellDirectorSell20,000$69.16$1,383,200.00View SEC Filing  
8/3/2016David PendarvisInsiderSell6,000$68.86$413,160.00View SEC Filing  
7/15/2016Michael J FarrellCEOSell5,975$65.03$388,554.25View SEC Filing  
7/14/2016James HollingsheadInsiderSell2,753$65.02$179,000.06View SEC Filing  
7/7/2016Peter C FarrellDirectorSell20,000$63.62$1,272,400.00View SEC Filing  
7/5/2016David PendarvisInsiderSell6,000$63.62$381,720.00View SEC Filing  
6/15/2016James HollingsheadInsiderSell4,458$59.40$264,805.20View SEC Filing  
6/15/2016Michael J FarrellCEOSell5,975$59.63$356,289.25View SEC Filing  
6/6/2016Peter C FarrellDirectorSell20,000$59.82$1,196,400.00View SEC Filing  
6/3/2016David PendarvisInsiderSell6,000$59.41$356,460.00View SEC Filing  
5/16/2016Michael J FarrellCEOSell5,975$57.64$344,399.00View SEC Filing  
5/4/2016Peter C FarrellDirectorSell20,000$55.90$1,118,000.00View SEC Filing  
5/3/2016David PendarvisInsiderSell6,000$56.02$336,120.00View SEC Filing  
4/15/2016Michael J FarrellCEOSell5,975$59.34$354,556.50View SEC Filing  
4/4/2016David PendarvisInsiderSell6,000$58.70$352,200.00View SEC Filing  
4/4/2016Peter C FarrellDirectorSell20,000$57.51$1,150,200.00View SEC Filing  
3/15/2016James HollingsheadInsiderSell4,500$58.57$263,565.00View SEC Filing  
3/15/2016Michael J FarrellCEOSell5,975$58.57$349,955.75View SEC Filing  
3/11/2016Gary W PaceDirectorSell36,000$60.00$2,160,000.00View SEC Filing  
3/4/2016Peter C FarrellDirectorSell20,000$57.51$1,150,200.00View SEC Filing  
3/3/2016David PendarvisInsiderSell6,000$57.26$343,560.00View SEC Filing  
2/29/2016Anne ReiserInsiderSell1,946$57.06$111,038.76View SEC Filing  
2/26/2016Brett SandercockCFOSell30,000$57.61$1,728,300.00View SEC Filing  
2/26/2016Richard SulpizioDirectorSell36,000$57.88$2,083,680.00View SEC Filing  
2/25/2016Peter C FarrellDirectorSell139,980$57.31$8,022,253.80View SEC Filing  
2/16/2016Michael J. FarrellCEOSell5,975$58.20$347,745.00View SEC Filing  
2/4/2016Peter C. FarrellDirectorSell20,000$57.70$1,154,000.00View SEC Filing  
2/3/2016David PendarvisinsiderSell6,000$57.43$344,580.00View SEC Filing  
1/27/2016Franz KozichDirectorBuy60,000$0.04$2,100.00
1/15/2016Michael J. FarrellCEOSell5,975$53.07$317,093.25View SEC Filing  
1/4/2016David PendarvisinsiderSell6,000$52.16$312,960.00View SEC Filing  
1/4/2016Peter C. FarrellDirectorSell20,000$52.22$1,044,400.00View SEC Filing  
1/4/2016Robert Andrew DouglasCOOSell6,337$52.97$335,670.89View SEC Filing  
12/15/2015James HollingsheadInsiderSell4,500$55.95$251,775.00View SEC Filing  
12/3/2015David PendarvisinsiderSell6,000$59.38$356,280.00View SEC Filing  
12/1/2015Robert Andrew DouglasCOOSell6,333$59.77$378,523.41View SEC Filing  
11/25/2015Warren Russell HawkinsDirectorBuy15,000$0.06$825.00
11/24/2015Warren Russell HawkinsDirectorBuy3,000$0.06$165.00
11/20/2015Christopher G RobertsDirectorSell12,000$59.03$708,360.00View SEC Filing  
11/16/2015Michael J. FarrellCEOSell5,975$57.03$340,754.25View SEC Filing  
11/12/2015Donald DarkininsiderSell25,442$57.72$1,468,512.24View SEC Filing  
11/2/2015Robert Andrew DouglasCOOSell6,333$57.60$364,780.80View SEC Filing  
10/27/2015Anne ReiserinsiderSell3,000$57.01$171,030.00View SEC Filing  
10/15/2015Michael J. FarrellCEOSell5,975$55.35$330,716.25View SEC Filing  
10/5/2015David PendarvisinsiderSell5,500$52.47$288,585.00View SEC Filing  
10/5/2015Robert Andrew DouglasCOOSell6,333$52.13$330,139.29View SEC Filing  
10/1/2015Peter C. FarrellChairmanSell27,169$50.93$1,383,717.17View SEC Filing  
9/15/2015James HollingsheadInsiderSell4,455$50.67$225,734.85View SEC Filing  
9/15/2015Michael J. FarrellCEOSell5,975$50.89$304,067.75View SEC Filing  
9/3/2015David PendarvisinsiderSell5,500$51.78$284,790.00View SEC Filing  
9/3/2015Robert Andrew DouglasCOOSell6,333$52.04$329,569.32View SEC Filing  
9/1/2015Peter C. FarrellChairmanSell36,000$50.82$1,829,520.00View SEC Filing  
8/28/2015Anne ReiserinsiderSell6,000$52.26$313,560.00View SEC Filing  
8/27/2015Richard SulpizioDirectorSell10,860$51.83$562,873.80View SEC Filing  
8/17/2015Michael J FarrellCEOSell5,975$55.54$331,851.50View SEC Filing  
7/15/2015Michael J FarrellCEOSell5,975$57.59$344,100.25View SEC Filing  
7/6/2015David PendarvisInsiderSell5,500$55.19$303,545.00View SEC Filing  
7/1/2015Peter C FarrellChairmanSell36,000$55.61$2,001,960.00View SEC Filing  
7/1/2015Robert Andrew DouglasCOOSell6,333$56.59$358,384.47View SEC Filing  
6/15/2015Michael J FarrellCEOSell5,975$57.87$345,773.25View SEC Filing  
6/3/2015David PendarvisInsiderSell5,500$59.41$326,755.00View SEC Filing  
6/1/2015Peter C FarrellChairmanSell36,000$59.25$2,133,000.00View SEC Filing  
6/1/2015Robert Andrew DouglasCOOSell6,333$59.22$375,040.26View SEC Filing  
5/4/2015David PendarvisInsiderSell5,500$65.10$358,050.00View SEC Filing  
4/6/2015David PendarvisInsiderSell5,500$72.60$399,300.00View SEC Filing  
4/1/2015Peter C FarrellChairmanSell36,000$70.70$2,545,200.00View SEC Filing  
4/1/2015Robert Andrew DouglasCOOSell6,333$70.67$447,553.11View SEC Filing  
3/27/2015Warren Russell HawkinsDirectorBuy10,000$0.09$900.00
3/26/2015Warren Russell HawkinsDirectorBuy10,000$0.08$800.00
3/16/2015Anne ReiserInsiderSell4,000$69.10$276,400.00View SEC Filing  
3/16/2015Michael J FarrellCEOSell5,975$69.10$412,872.50View SEC Filing  
3/9/2015Anne ReiserInsiderSell3,000$66.75$200,250.00View SEC Filing  
3/2/2015Peter C FarrellChairmanSell36,000$64.64$2,327,040.00View SEC Filing  
3/2/2015Robert Andrew DouglasCOOSell6,333$64.39$407,781.87View SEC Filing  
2/17/2015Anne ReiserInsiderSell5,000$66.11$330,550.00View SEC Filing  
2/5/2015David PendarvisInsiderSell5,500$62.35$342,925.00View SEC Filing  
2/4/2015John P WarehamDirectorSell36,000$63.49$2,285,640.00View SEC Filing  
2/3/2015Brett SandercockCFOSell18,670$62.82$1,172,849.40View SEC Filing  
2/3/2015Robert Andrew DouglasCOOSell6,333$62.35$394,862.55View SEC Filing  
2/2/2015Peter C FarrellChairmanSell36,000$61.97$2,230,920.00View SEC Filing  
1/26/2015Gary W PaceDirectorSell48,000$66.77$3,204,960.00View SEC Filing  
1/5/2015David PendarvisInsiderSell5,500$57.09$313,995.00View SEC Filing  
1/2/2015Peter C FarrellChairmanSell36,000$56.99$2,051,640.00View SEC Filing  
1/2/2015Robert Andrew DouglasCOOSell8,000$56.99$455,920.00View SEC Filing  
12/1/2014Peter C FarrellChairmanSell36,000$53.28$1,918,080.00View SEC Filing  
12/1/2014Robert Andrew DouglasCOOSell8,000$52.93$423,440.00View SEC Filing  
11/18/2014Peter C FarrellChairmanSell36,000$52.39$1,886,040.00View SEC Filing  
11/3/2014David PendarvisInsiderSell3,557$52.00$184,964.00View SEC Filing  
11/3/2014Robert Andrew DouglasCOOSell8,000$51.84$414,720.00View SEC Filing  
10/29/2014Peter C FarrellChairmanSell119,204$51.84$6,179,535.36View SEC Filing  
10/3/2014David PendarvisInsiderSell5,000$49.84$249,200.00View SEC Filing  
10/1/2014Robert Andrew DouglasCOOSell8,000$49.11$392,880.00View SEC Filing  
9/15/2014Michael J FarrellCEOSell3,200$52.41$167,712.00View SEC Filing  
9/5/2014Brett SandercockCFOSell10,000$52.99$529,900.00View SEC Filing  
9/3/2014Brett SandercockCFOSell10,000$53.23$532,300.00View SEC Filing  
9/3/2014David PendarvisInsiderSell5,000$53.23$266,150.00View SEC Filing  
8/22/2014Anne ReiserInsiderSell3,000$53.37$160,110.00View SEC Filing  
8/4/2014David PendarvisInsiderSell5,000$49.12$245,600.00View SEC Filing  
8/1/2014Peter C FarrellDirectorSell25,000$49.04$1,226,000.00View SEC Filing  
8/1/2014Robert Andrew DouglasCOOSell8,000$48.95$391,600.00View SEC Filing  
7/15/2014Michael J FarrellCEOSell3,200$49.22$157,504.00View SEC Filing  
7/3/2014David PendarvisInsiderSell5,000$50.04$250,200.00View SEC Filing  
7/1/2014Peter C FarrellDirectorSell25,000$50.09$1,252,250.00View SEC Filing  
7/1/2014Robert Andrew DouglasCOOSell8,000$50.11$400,880.00View SEC Filing  
6/16/2014Michael J FarrellCEOSell3,200$53.20$170,240.00View SEC Filing  
6/3/2014David PendarvisInsiderSell5,000$49.76$248,800.00View SEC Filing  
6/2/2014Peter C FarrellDirectorSell25,000$49.57$1,239,250.00View SEC Filing  
6/2/2014Robert Andrew DouglasCOOSell8,000$50.11$400,880.00View SEC Filing  
5/29/2014Christopher G RobertsDirectorSell25,000$49.73$1,243,250.00View SEC Filing  
5/15/2014Michael FarrellCEOSell3,700$50.54$186,998.00View SEC Filing  
5/13/2014John WarehamDirectorSell18,000$51.00$918,000.00View SEC Filing  
5/8/2014Brett SandercockCFOSell5,000$50.00$250,000.00View SEC Filing  
5/6/2014Brett SandercockCFOSell4,290$50.00$214,500.00View SEC Filing  
5/1/2014Peter FarrellDirectorSell25,000$49.80$1,245,000.00View SEC Filing  
5/1/2014Robert Andrew DouglasCOOSell8,000$49.75$398,000.00View SEC Filing  
4/29/2014David PendarvisInsiderSell15,000$50.01$750,150.00View SEC Filing  
4/21/2014Peter FarrellDirectorSell75,000$48.01$3,600,750.00View SEC Filing  
4/4/2014David PendarvisInsiderSell5,000$44.95$224,750.00View SEC Filing  
2/12/2014Brett SandercockCFOSell10,687$46.00$491,602.00View SEC Filing  
1/9/2014Peter FarrellDirectorSell25,000$48.00$1,200,000.00View SEC Filing  
12/2/2013Robert Andrew DouglasCOOSell8,000$49.10$392,800.00View SEC Filing  
11/20/2013Brett SandercockCFOSell15,000$51.06$765,900.00View SEC Filing  
11/20/2013James HollingsheadInsiderSell4,000$51.24$204,960.00View SEC Filing  
11/12/2013Donald DarkinInsiderSell31,063$50.04$1,554,392.52View SEC Filing  
10/29/2013David PendarvisInsiderSell37,744$50.42$1,903,052.48View SEC Filing  
10/1/2013Peter C FarrellDirectorSell25,000$53.21$1,330,250.00View SEC Filing  
10/1/2013Robert Andrew DouglasCOOSell8,000$53.20$425,600.00View SEC Filing  
9/9/2013Gary W PaceDirectorSell12,000$50.05$600,600.00View SEC Filing  
9/5/2013Peter C FarrellDirectorSell25,000$48.00$1,200,000.00View SEC Filing  
9/3/2013Robert Andrew DouglasCOOSell8,000$47.51$380,080.00View SEC Filing  
8/28/2013Michael QuinnDirectorSell48,000$48.34$2,320,320.00View SEC Filing  
8/27/2013Brett SandercockCFOSell5,000$49.00$245,000.00View SEC Filing  
8/26/2013Christopher RobertsDirectorSell10,000$49.49$494,900.00View SEC Filing  
8/1/2013Robert Andrew DouglasCOOSell8,000$48.57$388,560.00View SEC Filing  
6/3/2013Robert Andrew DouglasCOOSell8,000$47.96$383,680.00View SEC Filing  
5/24/2013Christopher G RobertsDirectorSell20,000$49.45$989,000.00View SEC Filing  
5/22/2013John P WarehamDirectorSell18,000$50.20$903,600.00View SEC Filing  
5/13/2013Michael A QuinnDirectorSell15,000$50.94$764,100.00View SEC Filing  
5/8/2013Brett SandercockCFOSell28,000$48.97$1,371,160.00View SEC Filing  
2/4/2013Robert Andrew DouglasCOOSell8,000$44.14$353,120.00View SEC Filing  
8/8/2012Michael J FarrellInsiderSell30,000$35.58$1,067,400.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for ResMed (NYSE:RMD)
Latest Headlines for ResMed (NYSE:RMD)
Source:
DateHeadline
americanbankingnews.com logoResMed Inc. (NYSE:RMD) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - July 24 at 6:52 PM
nasdaq.com logoIs a Surprise in Store for ResMed (RMD) in Q4 Earnings? - Nasdaq
www.nasdaq.com - July 22 at 8:17 AM
finance.yahoo.com logoIs a Surprise in Store for ResMed (RMD) in Q4 Earnings?
finance.yahoo.com - July 22 at 8:17 AM
americanbankingnews.com logoJames Hollingshead Sells 7,140 Shares of ResMed Inc. (RMD) Stock
www.americanbankingnews.com - July 17 at 4:26 PM
nasdaq.com logoResMed Sees Potential in SDB Market, Eyes Global Growth - Nasdaq
www.nasdaq.com - July 9 at 12:08 AM
americanbankingnews.com logo$548.75 Million in Sales Expected for ResMed Inc. (RMD) This Quarter
www.americanbankingnews.com - July 7 at 11:34 AM
americanbankingnews.com logoResMed Inc. (NYSE:RMD) Director Peter C. Farrell Sells 20,000 Shares
www.americanbankingnews.com - July 6 at 7:23 PM
americanbankingnews.com logoResMed Inc. (RMD) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - July 6 at 11:32 AM
americanbankingnews.com logoZacks: Analysts Expect ResMed Inc. (RMD) to Announce $0.75 EPS
www.americanbankingnews.com - July 5 at 8:28 PM
americanbankingnews.com logoInsider Selling: ResMed Inc. (NYSE:RMD) CFO Sells 1,250 Shares of Stock
www.americanbankingnews.com - July 5 at 7:45 PM
americanbankingnews.com logoResMed Inc. (RMD) Insider David Pendarvis Sells 6,364 Shares
www.americanbankingnews.com - July 5 at 7:28 PM
finance.yahoo.com logoResMed to Announce Fourth Quarter Fiscal Year 2017 Results
finance.yahoo.com - June 30 at 6:16 AM
americanbankingnews.com logoResMed Inc. (RMD) Insider Buys $19,740.00 in Stock
www.americanbankingnews.com - June 29 at 8:36 PM
americanbankingnews.com logoResMed Inc. (RMD) Insider Purchases $25,440.00 in Stock
www.americanbankingnews.com - June 29 at 4:28 PM
americanbankingnews.com logoResMed Inc. (RMD) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - June 28 at 1:50 PM
americanbankingnews.com logoResMed Inc. (RMD) Director Richard Sulpizio Sells 65,887 Shares
www.americanbankingnews.com - June 27 at 10:32 PM
americanbankingnews.com logoResMed Inc. (RMD) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - June 27 at 6:40 PM
nasdaq.com logoIJH, RMD, DRE, MSCI: ETF Outflow Alert - Nasdaq
www.nasdaq.com - June 27 at 7:49 AM
zacks.com logoResMed (RMD) at 52-Week High: What's Driving the Stock?
www.zacks.com - June 21 at 4:26 AM
americanbankingnews.com logoResMed Inc. (RMD) Upgraded to "Strong-Buy" at BidaskClub
www.americanbankingnews.com - June 17 at 4:12 PM
americanbankingnews.com logoResMed Inc. (RMD) Director Gary W. Pace Sells 24,390 Shares
www.americanbankingnews.com - June 16 at 1:24 PM
seekingalpha.com logoResMed (RMD) Presents At The William Blair 2017 Growth Stock Conference - Slideshow
seekingalpha.com - June 15 at 12:10 AM
finance.yahoo.com logoSleep Apnea Treatment Provider Enters New Buy Zone
finance.yahoo.com - June 15 at 12:10 AM
americanbankingnews.com logoZacks: Analysts Expect ResMed Inc. (RMD) Will Announce Quarterly Sales of $548.75 Million
www.americanbankingnews.com - June 11 at 8:06 AM
americanbankingnews.com logoZacks: Brokerages Anticipate ResMed Inc. (RMD) to Post $0.75 Earnings Per Share
www.americanbankingnews.com - June 9 at 10:32 PM
americanbankingnews.com logoResMed Inc. (RMD) Insider David Pendarvis Sells 6,365 Shares
www.americanbankingnews.com - June 6 at 4:29 PM
americanbankingnews.com logoPeter C. Farrell Sells 20,000 Shares of ResMed Inc. (RMD) Stock
www.americanbankingnews.com - June 6 at 4:29 PM
americanbankingnews.com logoBrett Sandercock Sells 1,250 Shares of ResMed Inc. (RMD) Stock
www.americanbankingnews.com - June 5 at 4:20 PM
americanbankingnews.com logoResMed Inc. (RMD) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - June 2 at 8:24 AM
fool.com logo2 of the best shares to profit from a falling Australian dollar
www.fool.com.au - May 30 at 7:14 PM
finance.yahoo.com logoETFs with exposure to ResMed, Inc. : May 25, 2017
finance.yahoo.com - May 26 at 6:33 AM
nasdaq.com logoNotable ETF Outflow Detected - IJH, ANSS, RMD, PKG
www.nasdaq.com - May 22 at 6:40 PM
finance.yahoo.com logoClinical Trial Published in JAMA Offers New Hope for COPD Patients
finance.yahoo.com - May 21 at 6:35 PM
nasdaq.com logoResMed Plans To Renew Patent Infringement Case Against Fisher & Paykel In ITC
www.nasdaq.com - May 17 at 7:29 PM
americanbankingnews.com logoResMed Inc. (RMD) Expected to Announce Quarterly Sales of $548.75 Million
www.americanbankingnews.com - May 17 at 11:18 AM
americanbankingnews.com logoResMed Inc. (RMD) Expected to Post Earnings of $0.75 Per Share
www.americanbankingnews.com - May 15 at 12:34 PM
americanbankingnews.com logoResMed Inc. (RMD) Earns Hold Rating from BMO Capital Markets
www.americanbankingnews.com - May 12 at 4:40 PM
nasdaq.com logoResMed Inc. (RMD) Ex-Dividend Date Scheduled for May 09, 2017 - Nasdaq
www.nasdaq.com - May 10 at 11:13 AM
nasdaq.com logoEx-Dividend Reminder: Starbucks, Entergy and ResMed
www.nasdaq.com - May 5 at 7:54 PM
americanbankingnews.com logoResMed Inc. (RMD) Director Peter C. Farrell Sells 20,000 Shares
www.americanbankingnews.com - May 5 at 1:51 PM
americanbankingnews.com logoDavid Pendarvis Sells 6,365 Shares of ResMed Inc. (RMD) Stock
www.americanbankingnews.com - May 5 at 1:50 PM
fool.com logoWhy Motley Fool Co-Founder David Gardner Likes ResMed Inc.
www.fool.com - May 4 at 9:49 AM
americanbankingnews.com logoResMed Inc. (RMD) CFO Brett Sandercock Sells 1,250 Shares
www.americanbankingnews.com - May 3 at 7:32 PM
americanbankingnews.com logoFavorable News Coverage Likely to Affect ResMed (RMD) Stock Price
www.americanbankingnews.com - May 3 at 1:03 AM
finance.yahoo.com logoETFs with exposure to ResMed, Inc. : May 2, 2017
finance.yahoo.com - May 2 at 5:23 PM
americanbankingnews.com logoResMed Inc. (RMD) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - May 1 at 10:38 PM
finance.yahoo.com logoResMed, Inc. :RMD-US: Earnings Analysis: Q3, 2017 By the Numbers : May 1, 2017
finance.yahoo.com - May 1 at 6:51 PM
americanbankingnews.com logoJefferies Group Analysts Lower Earnings Estimates for ResMed Inc. (RMD)
www.americanbankingnews.com - May 1 at 11:32 AM
americanbankingnews.com logoWilliam Blair Brokers Cut Earnings Estimates for ResMed Inc. (RMD)
www.americanbankingnews.com - May 1 at 9:36 AM
americanbankingnews.com logoResMed (RMD) Receives Media Impact Score of 0.20
www.americanbankingnews.com - April 29 at 11:33 PM

Social

Chart

ResMed (RMD) Chart for Tuesday, July, 25, 2017

This page was last updated on 7/25/2017 by MarketBeat.com Staff